.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,638,932

« Back to Dashboard

Details for Patent: 6,638,932

Title: 2,4-disubstituted triazine derivatives
Abstract:This invention concerns the use of the compounds of formula ##STR1## the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein --a.sup.1.dbd.a.sup.2 --a.sup.3.dbd.a.sup.4 -- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R.sup.1 is hydrogen, aryl, formyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxycarbonyl or substituted C.sub.1-6 alkyl; each R.sup.2 independently is hydroxy, halo, optionally substituted C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C.sub.1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, --S(.dbd.O).sub.p R.sup.4, --NH--S(.dbd.O).sub.p R.sup.4, --C(.dbd.O)R.sup.4, --NHC(.dbd.O)H, --C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.4, --C(.dbd.NH)R.sup.4 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl or C.sub.3-7 cycloalkyl; or L is --X--R.sup.3 wherein R.sup.3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl; X is --NR.sup.1 --, --NH--NH--, --N.dbd.N--, --O--, --C(.dbd.O)--, --CHOH--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2 --; aryl is optionally substituted phenyl; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.
Inventor(s): De Corte; Bart (Southampton, PA), de Jonge; Marc Rene (Tilburg, NL), Heeres; Jan (Vosselaar, BE), Janssen; Paul Adriaan Jan (Vosselaar, BE), Kavash; Robert W. (Glenside, PA), Koymans; Lucien Maria Henricus (Retie, BE), Kukla; Michael Joseph (Maple Glen, PA), Ludovici; Donald William (Quakertown, PA), Van Aken; Koen Jeanne Alfons (Turnhout, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Filing Date:Aug 02, 2001
Application Number:09/831,808
Claims:1. A compound of formula ##STR11##

or a N-oxide, a pharmaceutically acceptable salt, or a stereochemically isomeric form thereof, wherein --a.sup.1.dbd.a.sup.2 --a.sup.3.dbd.a.sup.4 -- represents a bivalent radical of formula

with the proviso that compounds wherein L is --X--R.sup.3, X is --NH--; R.sup.1 is hydrogen; --a.sup.1.dbd.a.sup.2 --a.sup.3.dbd.a.sup.4 -- represents a bivalent radical of formula (a-1); n is 0 or 1 and R.sup.2 is selected from amino or nitro and R.sup.3 is phenyl, and the compound N,N'-dipyridinyl-(1,3,5)-triazine-2,4-diamine,

are not included.

2. A compound as claimed in claim 1 wherein L is --X--R.sup.3, --X-- is --O-- or --NH-- and R.sup.3 is phenyl substituted with two or three substituents each independently selected from chloro, bromo, cyano or methyl.

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compound as claimed in claim 1.

4. A process for preparing a pharmaceutical composition as claimed in claim 3 comprising mixing a therapeutically effective amount of said compound with a pharmaceutically acceptable carrier.

5. A process for preparing a compound as claimed in claim 1, comprising a) reacting an intermediate of formula (II) with an amine derivative of formula (III) and subsequently reacting the resulting intermediate of formula (IV) with an intermediate of formula (V) in a reaction-inert solvent in the presence of a suitable base; ##STR13## wherein W.sup.1 is a suitable leaving group; b) reacting an intermediate of formula (VI) with an intermediate of formula (VII) and subsequently reacting the resulting intermediate of formula (VIII) with an amine derivative of formula (III) in a reaction-inert solvent in the presence of a suitable base; ##STR14## wherein W.sup.1, W.sup.2 are suitable leaving groups, L.sub.a is optionally substituted C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, or C.sub.3-7 cycloalkyl;

or optionally, interconverting a first compound of formula (I') to yield a second compound of formula (I'), and further, optionally, converting compounds of formula (I') into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, optionally, preparing stereochemically isomeric forms or N-oxides thereof.

6. The combination of a compound as defined in claim 1 and another antiretroviral compound.

7. A combined preparation for simultaneous, separate or sequential use in anti-HIV treatment, comprising a product containing (a) a compound as defined in claim 1, and (b) another antiretroviral compound.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 1, and (b) another antiretroviral compound.

9. A method of treating a subject suffering from Human Immunodeficiency Virus (HIV) infection, comprising administering to said subject a therapeutically effective amount of a compound of formula ##STR15##

or a N-oxide, a pharmaceutically acceptable salt, or a stereochemically isomeric form thereof, wherein --a.sup.1.dbd.a.sup.2 --a.sup.3.dbd.a.sup.4 -- represents a bivalent radical of formula

10. The method of claim 9 further comprising administering a therapeutically effective amount of another antiretroviral compound to said subject.

11. The method of claim 10 where said compound of formula (I) and the other antiretroviral compound are administered simultaneously, separately, or sequentially to said subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc